Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset: Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang; Cancer Res Treat. 2024;56(1):48-60. Published online June 27, 2023; DOI: https://doi.org/10.4143/crt.2023.453

Abstract PDF Supplementary Material PubReader ePub

Purpose
This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).
Materials and Methods
Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results
In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion
Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.

Citations

Citations to this article as recorded by

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis
Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun, Chengbo Han
Scientific Reports.2024;[Epub] CrossRef

6,373 View
586 Download
3 Web of Science
1 Crossref

Current Status and Challenges of Cancer Clinical Trials in Korea: Byoung Yong Shim, Se Hoon Park, Soonil Lee, Jin-Soo Kim, Kyoung Eun Lee, Yoon-Koo Kang, Myung-Ju Ahn; Cancer Res Treat. 2016;48(1):20-27. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.317

Abstract PDF PubReader ePub

Purpose
Cancer clinical trials in Korea have rapidly progressed in terms of quantity and quality during the last decade. This study evaluates the current status of cancer clinical trials in Korea and their associated problems. Materials and Methods We analyzed the clinical trials approved by the Korea Food and Drug Administration (KFDA) between 2007 and 2013. A nationwide on-line survey containing 22 questions was also performed with several cooperative study groups and individual researchers in 56 academic hospitals.
Results
The number of cancer clinical trials approved by the KFDA increased almost twofold from 2007 to 2013. The number of sponsor-initiated clinical trials (SITs) increased by 50% and investigator-initiated clinical trials (IITs) increased by almost 640%. Three hundred and fortyfour clinical trials were approved by the KFDA between 2012 and 2013. At the time of the on-line survey (August 2013), 646 SITs and 519 IITs were ongoing in all hospitals. Six high volume hospitals were each conducting more than 50 clinical trials, including both SITs and IITs. Fifty-six investigators (31%) complained of the difficulties in raising funds to conduct clinical trials. Conclusion The number of cancer clinical trials in Korea rapidly increased from 2007 to 2013, as has the number of multicenter clinical trials and IITs run by cooperative study groups. Limited funding for IIT is a serious problem, and more financial support is needed both from government agencies and public donations from non-profit organizations.

Citations

Citations to this article as recorded by

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef
Trends of clinical trials from 2017 to 2019 in Korea: an integrated analysis based on the Ministry of Food and Drug Safety (MFDS) and the Clinical Research Information Service (CRIS) registries
Ki Young Huh, Kyung-Sang Yu, Hyeong-Seok Lim, Hyungsub Kim
Translational and Clinical Pharmacology.2021; 29(4): 186. CrossRef
Regional Differences in Access to Clinical Trials for Cancer in Korea
Woorim Kim, Seongkyeong Jang, Yoon Jung Chang
Quality Improvement in Health Care.2021; 27(1): 20. CrossRef
Effects of pharmacist interventions on reducing prescribing errors of investigational drugs in oncology clinical trials
Jin Young Moon, Yeonhong Lee, Ji Min Han, Mi Hyung Lee, Jeong Yee, Mi Kyung Song, Young Ju Kim, Hye Sun Gwak
Journal of Oncology Pharmacy Practice.2020; 26(1): 29. CrossRef
Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
Ankur Vaidya, Shweta Jain, Sanjeev Sahu, Pankaj Kumar Jain, Kamla Pathak, Devender Pathak, Raj Kumar, Sanjay Kumar Jain
Mini-Reviews in Medicinal Chemistry.2020; 20(10): 886. CrossRef
Linguistic Validation of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean
Juhee Cho, Junghee Yoon, Youngha Kim, Dongryul Oh, Seok Jin Kim, Jinseok Ahn, Gee Young Suh, Seok Jin Nam, Sandra A. Mitchell
Journal of Global Oncology.2019; (5): 1. CrossRef
Survey of Medical Oncology Status in Korea (SOMOS-K): A National Survey of Medical Oncologists in the Korean Association for Clinical Oncology (KACO)
Do Yeun Kim, Yun Gyoo Lee, Bong-Seog Kim
Cancer Research and Treatment.2017; 49(3): 588. CrossRef
Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate
Yoojoo Lim, Jee Min Lim, Won Jae Jeong, Kyung-Hun Lee, Bhumsuk Keam, Tae-Yong Kim, Tae Min Kim, Sae-Won Han, Do Youn Oh, Dong-Wan Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Seock-Ah Im
Cancer Research and Treatment.2017; 49(4): 1033. CrossRef

11,502 View
129 Download
8 Web of Science
8 Crossref

GRP78 Protein Expression as Prognostic Values in Neoadjuvant Chemoradiotherapy and Laparoscopic Surgery for Locally Advanced Rectal Cancer: Hee Yeon Lee, Ji-Han Jung, Hyun-Min Cho, Sung Hwan Kim, Kang-Moon Lee, Hyung-Jin Kim, Jong Hoon Lee, Byoung Yong Shim; Cancer Res Treat. 2015;47(4):804-812. Published online January 30, 2015; DOI: https://doi.org/10.4143/crt.2014.121

Abstract PDF PubReader ePub

Purpose
We investigated the relationships between biomarkers related to endoplasmic reticulum stress proteins (glucose-regulated protein of molecular mass 78 [GRP78] and Cripto-1 [teratocarcinoma-derived growth factor 1 protein]), pathologic response, and prognosis in locally advanced rectal cancer. Materials and Methods All clinical stage II and III rectal cancer patients received 50.4 Gy over 5.5 weeks, plus 5- fluorouracil (400 mg/m2/day) and leucovorin (20 mg/m2/day) bolus on days 1 to 5 and 29 to 33, and surgery was performed at 7 to 10 weeks after completion of all therapies. Expression of GRP78 and Cripto-1 proteins was determined by immunohistochemistry and was assessed in 101 patients with rectal cancer treated with neoadjuvant chemoradiotherapy (CRT).
Results
High expression of GRP78 and Cripto-1 proteins was observed in 86 patients (85.1%) and 49 patients (48.5%), respectively. Low expression of GRP78 protein was associated with a significantly high rate of down staging (80.0% vs. 52.3%, respectively; p=0.046) and a significantly low rate of recurrence (0% vs. 33.7%, respectively; p=0.008) compared with high expression of GRP78 protein. Mean recurrence-free survival according to GRP78 expression could not be estimated because the low expression group did not develop recurrence events but showed a significant correlation with time to recurrence, based on the log rank method (p=0.007). GRP78 also showed correlation with overall survival, based on the log rank method (p=0.045). Conclusion GRP78 expression is a predictive and prognostic factor for down staging, recurrence, and survival in rectal cancer patients treated with 5-fluorouracil and leucovorin neoadjuvant CRT.

Citations

Citations to this article as recorded by

Is GRP78 (Glucose-regulated protein 78) a prognostic biomarker in differents types of cancer? A systematic review and meta-analysis
Natália Souza dos Santos, Douglas Rodrigues Gonçalves, Bianca Balbinot, Fernanda Visioli
Pathology - Research and Practice.2023; 242: 154301. CrossRef
GRP78 is Overexpressed in Non-small Cell Lung Cancer Tissues and is Associated with High VEGF Expression in Squamous Cell Carcinoma: A Pilot Study
Maha Al-Keilani, Mohammad A. Alqudah, Basima Almomani, Moath M. Alrjoub, Batool A. Shhabat, Karem Alzoubi
Current Cancer Drug Targets.2023; 23(10): 805. CrossRef
GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first
Yi Tat Tong, Hua Wang, Dongguang Wei, Laura R. Prakash, Michael Kim, Ching-Wei D. Tzeng, Jeffrey E. Lee, Asif Rashid, Eugene J. Koay, Robert A. Wolff, Anirban Maitra, Matthew HG. Katz, Huamin Wang
Pancreatology.2021; 21(7): 1378. CrossRef
Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma
Tian Xia, Hui Tian, Kaiwen Zhang, Siyu Zhang, Wenhui Chen, Si Shi, Yiwen You
BMC Cancer.2021;[Epub] CrossRef
BCAP31, a cancer/testis antigen-like protein, can act as a probe for non-small-cell lung cancer metastasis
Jing Wang, Dongbo Jiang, Zichao Li, Shuya Yang, Jiayi Zhou, Guanwen Zhang, Zixin Zhang, Yuanjie Sun, Zhipei Zhang, Xiaofei Li, Liang Tao, Jingqi Shi, Yuchen Lu, Lianhe Zheng, Chaojun Song, Kun Yang
Scientific Reports.2020;[Epub] CrossRef
Prognostic Value of Cripto-1 Expression in Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
Yuanfeng Wei, Jinfang Jiang, Chengyan Wang, Hong Zou, Xihua Shen, Wei Jia, Shan Jin, Lu Zhang, Jianming Hu, Lan Yang, Lijuan Pang
Biomarkers in Medicine.2020; 14(4): 317. CrossRef
Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer
Tianming Zhao, Juan Du, Hui Zeng
Journal of Hematology & Oncology.2020;[Epub] CrossRef
Dual role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis
Natalia Siwecka, Wioletta Rozpędek, Dariusz Pytel, Adam Wawrzynkiewicz, Adam Dziki, Łukasz Dziki, J. Alan Diehl, Ireneusz Majsterek
International Journal of Molecular Sciences.2019; 20(18): 4354. CrossRef
Clinical and Pathological Significance of ER Stress Marker (BiP/GRP78 and PERK) Expression in Malignant Melanoma
Akira Shimizu, Kyoichi Kaira, Masahito Yasuda, Takayuki Asao, Osamu Ishikawa
Pathology & Oncology Research.2017; 23(1): 111. CrossRef
Effects of gene polymorphisms in the endoplasmic reticulum stress pathway on clinical outcomes of chemoradiotherapy in Chinese patients with nasopharyngeal carcinoma
Xiao-bin Guo, Wan-le Ma, Li-juan Liu, Yu-ling Huang, Jing Wang, Li-hua Huang, Xiang-dong Peng, Ji-ye Yin, Jin-gao Li, Shao-jun Chen, Guo-ping Yang, Hui Wang, Cheng-xian Guo
Acta Pharmacologica Sinica.2017; 38(4): 571. CrossRef
The meta and bioinformatics analysis of GRP78 expression in gastric cancer
Hua-Chuan Zheng, Bao-Cheng Gong, Shuang Zhao
Oncotarget.2017; 8(42): 73017. CrossRef
Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis
Y Pan, F Cao, A Guo, W Chang, X Chen, W Ma, X Gao, S Guo, C Fu, J Zhu
British Journal of Cancer.2015; 113(5): 763. CrossRef

12,999 View
76 Download
15 Web of Science
12 Crossref

The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients: Jeong Won Lee, Jong Hoon Lee, Hoon-Kyo Kim, Byoung Yong Shim, Ho Jung An, Sung Hwan Kim; Cancer Res Treat. 2015;47(2):189-196. Published online September 12, 2014; DOI: https://doi.org/10.4143/crt.2013.261

Abstract PDF PubReader ePub

Purpose
The objective of this study was to evaluate external beam radiotherapy (EBRT) in lung cancer patients who suffer from airway obstruction. Materials and Methods Medical data of 95 patients with a lung mass that obstructed the airway and received EBRT for it were analyzed. Fifty-nine patients (62.1%) had non-small cell lung cancer and 36 patients (37.9%) had small cell lung cancer. Radiotherapy was given at 8 to 45 Gy (median, 30 Gy) in 1 to 15 fractions (median, 10 fractions). The response to EBRT was assessed through changes in radiographic findings and/or subjective symptoms between before and after EBRT. The median follow-up duration was 124 days. The primary end point was the airway-obstruction resolving rate after EBRT. The secondary end points were patient survival and toxic effects of EBRT. Results Improvement of airway obstruction after EBRT on chest X-ray was achieved in 75 of 95 patients (78.9%). The median time for resolving the radiologic findings and/or symptoms of airway obstruction after EBRT was 7 days (range, 1 to 76 days). The 1-year survival rate was significantly higher in responders than non-responders (12.5% vs. 0.0%, p < 0.001). The biologically effective dose of ≥ 39 Gyα/β=10 (p < 0.01) and the longest obstructive lesion of < 6 cm (p=0.04) were significantly associated with a good response to EBRT in resolving the airway obstruction. No one had grade 3 or higher acute and chronic toxicities. Conclusion EBRT is an effective treatment in relieving airway obstruction without severe toxicities in lung cancer patients.

Citations

Citations to this article as recorded by

External Beam Radiotherapy for Malignant Central Airway Obstruction in a Remote Rural Patient: A Case Study
Eoin Collins, Druva Mitra, Scott Carruthers
Case Reports in Oncology.2024; 17(1): 1301. CrossRef
Mid-treatment adaptive planning during thoracic radiation using 68 Ventilation-Perfusion Positron emission tomography
Nicholas Bucknell, Nicholas Hardcastle, Roshini Gunewardena, Long Nguyen, Jason Callahan, David Ball, Lisa Selbie, Tomas Kron, Guy-Anne Turgeon, Michael S. Hofman, Shankar Siva
Clinical and Translational Radiation Oncology.2023; 40: 100599. CrossRef
Efficacy and Survival after Palliative Radiotherapy for Malignant Pulmonary Obstruction
Adam G. Johnson, Michael H. Soike, Michael K. Farris, Ryan T. Hughes
Journal of Palliative Medicine.2022; 25(1): 46. CrossRef
Therapeutic Rigid Bronchoscopy Intervention for Malignant Central Airway Obstruction Improves Performance Status to Allow Systemic Treatment
Edward Y.C. Lee, Annette M. McWilliams, Matthew R. Salamonsen
Journal of Bronchology & Interventional Pulmonology.2022; 29(2): 93. CrossRef
Malignant Central Airway Obstruction: What's New?
Brian D. Shaller, Darius Filsoof, Jorge M. Pineda, Thomas R. Gildea
Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 512. CrossRef
Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?
Weigang Xiu, Xiaotong Guo, Min Yu, Yanying Li, Yong Xu, Jiang Zhu, Jingjing Luo
Clinical Medicine Insights: Oncology.2022;[Epub] CrossRef
First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies
Nathaniel M. Ivanick, Emily R. Oakley, Rajesh Kunadharaju, Craig Brackett, David A. Bellnier, Lawrence M. Tworek, Sergei N. Kurenov, Sandra O. Gollnick, Alan D. Hutson, Theresa M. Busch, Gal Shafirstein
JTO Clinical and Research Reports.2022; 3(10): 100372. CrossRef
Electrospray Mediated Localized and Targeted Chemotherapy in a Mouse Model of Lung Cancer
Paulius Ruzgys, Stephan Böhringer, Ayse Sila Dokumaci, Yvonne Hari, Christian M. Schürch, Frido Brühl, Stefan Schürch, Sönke Szidat, Carsten Riether, Saulius Šatkauskas, Thomas Geiser, David Hradetzky, Amiq Gazdhar
Frontiers in Pharmacology.2021;[Epub] CrossRef
Role of radiotherapy in the management of malignant airway obstruction
Hoon Sik Choi, Bae Kwon Jeong, Hojin Jeong, In Bong Ha, Ki Mun Kang
Thoracic Cancer.2020; 11(8): 2163. CrossRef
Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy
Lonny Yarmus, Christopher Mallow, Jason Akulian, Cheng Ting Lin, David Ettinger, Russell Hales, Kinh Ranh Voong, Hans Lee, David Feller-Kopman, Roy Semaan, Kirk Seward, Momen M. Wahidi
Chest.2019; 156(3): 562. CrossRef
Functional airway obstruction observed with hyperpolarized 129Xenon‐MRI
Erin J Song, Chris R Kelsey, Bastiaan Driehuys, Leith Rankine
Journal of Medical Imaging and Radiation Oncology.2018; 62(1): 91. CrossRef
Endobronchial brachytherapy in the management of lung malignancies: 20 years of experience in an Australian center
Matthew C. Knox, Andrej Bece, Joseph Bucci, John Moses, Peter H. Graham
Brachytherapy.2018; 17(6): 973. CrossRef

13,731 View
92 Download
19 Web of Science
12 Crossref

Prognostic Role of Rb, p16, Cyclin D1 Proteins in Soft Tissue Sarcomas: Byoung Yong Shim, Jinyoung Yoo, Yeon-Soo Lee, Young Sun Hong, Hoon-Kyo Kim, Jin-Hyoung Kang; Cancer Res Treat. 2010;42(3):144-150. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.144

Abstract PDF PubReader ePub

Purpose

The aim of this study was to determine the expressions of Rb, p16, and cyclin D1 in soft tissue sarcomas, and we also wanted to identify the prognostic factors according to the clinicalpathologic features.

Materials and Methods

We reviewed the charts and radiographic films of 66 sarcoma patients. Tissue samples were collected from these patients. Immunochemistry was performed using formalin-fixed, paraffin-embedded tissue samples to examine the expressions of p16, Rb, and cyclin D1 proteins.

Results

The median duration of overall survival was 47.8 months (range, 20.0 to 70.7 months) and the 5 years survival rate was 39%. As for the correlation between the degree of immunohistochemical staining for Rb protein and the histological tumor grades, there was a significant difference with a p-value of 0.019. However, no significant correlation was shown for p16 and cyclin D1. The overall survival duration of the Rb negative group (staining cell <20%) and the heterogeneous group (cell staining 20 to 80%) was 53.5±6.6 months and the overall survival duration of the Rb homogeneous group was 18.3±6.4 months, and there was a significant difference with a p-value of 0.016. However, no significant difference was shown between the survival rate according to the p16 and cyclin D1 expressions. On the multivariate analysis that was done with Rb, p16, the tumor size, grade and site, and patient age, the Rb gene expression was the most significant independent prognostic factor with a risk ratio of 3.01 (p=0.04).

Conclusion

The expression of Rb protein was correlated with the histologic grade and overall survival of patients with soft tissue sarcomas.

Citations

Citations to this article as recorded by

Immunohistochemical Expression of p16 and CDK4 in Soft Tissue Tumors
Mala Sagar, Rita Yadav, Pankaj Deval, Madhu Kumar, Malti K Maurya, Sumaira Qayoom
Cureus.2023;[Epub] CrossRef
Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas
Jaffar Khan, Liang Cheng, Michael G. House, Shunhua Guo
Current Oncology.2021; 28(6): 5295. CrossRef
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
Laboratory Investigation.2019; 99(9): 1309. CrossRef
Prognostic significance of p16INK4a alteration in soft tissue sarcomas: A meta-analysis
Gang Lin, Yue Lou
Indian Journal of Cancer.2017; 54(3): 580. CrossRef
GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas
Toshiaki Haraguchi, Hiroaki Miyoshi, Koji Hiraoka, Shintaro Yokoyama, Yukinao Ishibashi, Toshihiro Hashiguchi, Koutaro Matsuda, Tetsuya Hamada, Takahiro Okawa, Naoto Shiba, Koichi Ohshima, Ichiro Aoki
PLOS ONE.2016; 11(6): e0156524. CrossRef
Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
Elisabetta Pennacchioli, Giulio Tosti, Massimo Barberis, Tommaso M. De Pas, Francesco Verrecchia, Claudia Menicanti, Alessandro Testori, Giovanni Mazzarol
Clinical & Experimental Metastasis.2012; 29(7): 757. CrossRef

10,292 View
65 Download
6 Crossref

Predictors of Axillary Lymph Node Metastases (ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer has a High Incidence of ALNM Irrespective of the Tumor Size: Jong Hoon Lee, Sung Hwan Kim, Young Jin Suh, Byoung Yong Shim, Hoon Kyo Kim; Cancer Res Treat. 2010;42(1):30-36. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.30

Abstract PDF PubReader ePub

Purpose

We estimated the likelihood of breast cancer patients having axillary lymph node metastases (ALNM) based on a variety of clinical and pathologic factors.

Materials and Methods

Three hundred sixty-one breast cancer patients without distant metastases and who underwent breast conserving surgery and axillary lymph node dissection (ALND) (level I and II) or modified radical mastectomy (MRM) were identified, and we retrospectively reviewed their pathology records and treatment charts.

Results

Positive axillary lymph nodes were detected in 104 patients for an overall incidence of 28.8%: 2 patients (5%) with T1a tumor, 5 (9.2%) with T1b tumor, 24 (21.8%) with T1c tumor and 73 (44.2%) with T2 tumor. On the multivariate analysis, an increased tumor size (adjusted OR=11.87, p=0.02), the presence of lymphovascular invasion (adjusted OR=7.41, p<0.01), a triple negative profile (ER/PR-, Her2-) (adjusted OR=2.09, p=0.04) and a palpable mass at the time of diagnosis (adjusted OR=2.31, p=0.03) were all significant independent factors for positive ALNM.

Conclusion

In our study, the tumor size, the presence of lymphovascular invasion, a triple negative profile and a palpable mass were the independent predictive factors for ALNM. The tumor size was the strongest predictor of ALNM. Thus, the exact estimation of the extent of tumor is necessary for clinicians to optimize the patients' care. Patients with a triple negative profile have a high incidence of ALNM irrespective of the tumor size.

Citations

Citations to this article as recorded by

Is Programmed Death-Ligand 1 of Prognostic Significance in Triple-Negative Female Mammary Carcinoma?
Amal Mostafa Sanad, Wael Shawky Ibrahim, Iman Mohamed Ezzo, Rania Mohamed Sabry
Journal of Microscopy and Ultrastructure.2024; 12(1): 6. CrossRef
AXILLARY LYMPH NODE METASTASIS IN SONOLOGICALLY NODE-NEGATIVE BREAST CARCINOMA
ADARSA S BABU, SUNIL S, JOMINE JOSE
Asian Journal of Pharmaceutical and Clinical Research.2024; : 26. CrossRef
Is routine axillary staging still required in clinically node negative early breast cancer in women over 74 years?
Katherine Grant, Xiang Yuen Po, Leong Tiong
ANZ Journal of Surgery.2024; 94(12): 2159. CrossRef
Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival
Billy Shui‐Wun Lai, Julia Y Tsang, Joshua J Li, Ivan K Poon, Gary M Tse
Histopathology.2023; 82(6): 899. CrossRef
CORRELATION OF RECEPTOR STATUS WITH AXILLARY NODAL METASTASIS AND OTHER PROGNOSTIC FACTORS IN CARCINOMA BREAST : INDIAN PERSPECTIVE
Mohammad Raja, Shailendra Rai, Aklesh Kumar Maurya, Basanti Mazumdar
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2022; : 30. CrossRef
Isocorrole-Loaded Polymer Nanoparticles for Photothermal Therapy under 980 nm Light Excitation
Maximilian R. J. Marek, Trong-Nhan Pham, Jianxin Wang, Qiuqi Cai, Glenn P. A. Yap, Emily S. Day, Joel Rosenthal
ACS Omega.2022; 7(41): 36653. CrossRef
Differences in the Immune Response of the Nonmetastatic Axillary Lymph Nodes between Triple-Negative and Luminal A Breast Cancer Surrogate Subtypes
Carlos López, Albert Gibert-Ramos, Ramón Bosch, Anna Korzynska, Marcial García-Rojo, Gloria Bueno, Joan Francesc García-Fontgivell, Salomé Martínez González, Laia Fontoura, Andrea Gras Navarro, Esther Sauras Colón, Júlia Casanova Ribes, Lukasz Roszkowiak,
The American Journal of Pathology.2021; 191(3): 545. CrossRef
Axillary management based on American college of surgeons oncology group Z0011 criteria makes it possible to omit intraoperative diagnosis of sentinel lymph nodes in early breast cancer patients
Nobuyoshi Kittaka, Satomi Nakajima, Takaaki Hatano, Yukiko Seto, Hiroki Kusama, Saki Matsui, Minako Nishio, Fumie Fujisawa, Keiichiro Honma, Takahiro Nakayama, Yasuhiro Tamaki
The Breast Journal.2021; 27(11): 804. CrossRef
Development of a Novel Tool for the Retrieval and Analysis of Hormone Receptor Expression Characteristics in Metastatic Breast Cancer via Data Mining on Pathology Reports
Kai-Po Chang, John Wang, Chi-Chang Chang, Yen-Wei Chu, Yungang Xu
BioMed Research International.2020;[Epub] CrossRef
Accuracy of CEUS-guided sentinel lymph node biopsy in early-stage breast cancer: a study review and meta-analysis
Qiuxia Cui, Li Dai, Jialu Li, Jialei Xue
World Journal of Surgical Oncology.2020;[Epub] CrossRef
Preoperative Axillary Ultrasound Helps in the Identification of a Limited Nodal Burden in Breast Cancer Patients
Haiyu Luo, Yongqian Mo, Jieyu Zhong, Yushen Zhang, Lizhang Zhu, Xiaoxin Shi, Yun Chen
Ultrasound Quarterly.2020; 36(2): 173. CrossRef
Lymph node positivity in different early breast carcinoma phenotypes: a predictive model
Gilles Houvenaeghel, Eric Lambaudie, Jean-Marc Classe, Chafika Mazouni, Sylvia Giard, Monique Cohen, Christelle Faure, Hélène Charitansky, Roman Rouzier, Emile Daraï, Delphine Hudry, Pierre Azuar, Richard Villet, Pierre Gimbergues, Christine Tunon de Lara
BMC Cancer.2019;[Epub] CrossRef
Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis
Eun-Kyu Kim, Ae Kyung Park, Eunyoung Ko, Woong-Yang Park, Kyung-Min Lee, Dong-Young Noh, Wonshik Han
Breast Cancer Research and Treatment.2019; 178(1): 185. CrossRef
Preoperative Axillary Ultrasound in the Selection of Patients With a Heavy Axillary Tumor Burden in Early‐Stage Breast Cancer: What Leads to False‐Positive Results?
Ying Zhu, Wei Zhou, Xiao‐hong Jia, Ou Huang, Wei‐wei Zhan
Journal of Ultrasound in Medicine.2018; 37(6): 1357. CrossRef
Clinical implication of subcategorizing T2 category into T2a and T2b in TNM staging of breast cancer
Jiwoong Jung, Young Jin Suh, Byung Kyun Ko, Eun Sook Lee, Eun‐Kyu Kim, Nam Sun Paik, Kyung Do Byun, Ki‐Tae Hwang
Cancer Medicine.2018; 7(11): 5514. CrossRef
A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran
Roham Salek, Fatemeh Varshoee Tabrizi, Kamran Ghaffarzadegan, Golnaz Sabouri, Azar Fanipakdel
Iranian Journal of Cancer Prevention.2017;[Epub] CrossRef
Risk Stratification For Axillary Lymph Node Metastases in Breast Cancer Patients
Seong Jong Yun, Yu-Mee Sohn, Mirinae Seo
Ultrasound Quarterly.2017; 33(1): 15. CrossRef
Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis
Young-Sil An, Doo Kyoung Kang, Yongsik Jung, Tae Hee Kim
Medicine.2017; 96(45): e8557. CrossRef
The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer
Keun-Yong Eom, Min Hye Jang, So Yeon Park, Eun Young Kang, Sung Won Kim, Jee Hyun Kim, Jae-Sung Kim, In Ah Kim
Cancer Research and Treatment.2016; 48(1): 125. CrossRef
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer
Katsutoshi Enokido, Chie Watanabe, Seigo Nakamura, Akiko Ogiya, Tomo Osako, Futoshi Akiyama, Akiyo Yoshimura, Hiroji Iwata, Shinji Ohno, Yasuyuki Kojima, Koichiro Tsugawa, Kazuyoshi Motomura, Naoki Hayashi, Hideko Yamauchi, Nobuaki Sato
Clinical Breast Cancer.2016; 16(4): 299. CrossRef
Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer
Mi Joo Chung, Jong Hoon Lee, Sung Hwan Kim, Young Jin Suh, Hyun Joo Choi
Medicine.2016; 95(20): e3689. CrossRef
Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer
Riccardo Ponzone, Fiorella Ruatta, Marco Gatti, Isabella Castellano, Elena Geuna, Giulia Amato, Franziska Kubatzki, Paola Sgandurra, Anna Sapino, Filippo Montemurro
Cancer Treatment Reviews.2016; 48: 1. CrossRef
HER2 expression is a strong independent predictor of nodal metastasis in breast cancer
Ahmed R.H. Ahmed
Journal of the Egyptian National Cancer Institute.2016; 28(4): 219. CrossRef
Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression
Manjulata Singh, Shilpaa Mukundan, Maria Jaramillo, Steffi Oesterreich, Shilpa Sant
Cancer Research.2016; 76(13): 3732. CrossRef
Reduced risk of axillary lymphatic spread in triple-negative breast cancer
Emil Villiam Holm-Rasmussen, Maj-Britt Jensen, Eva Balslev, Niels Kroman, Tove Filtenborg Tvedskov
Breast Cancer Research and Treatment.2015; 149(1): 229. CrossRef
Evaluation of the Flash effect in breast irradiation using TomoDirect: an investigational study
Dae Gyu Kang, Sung Ill Park, Sung Hwan Kim, Mi Joo Chung, Kwang-Man Lee, Jong Hoon Lee
Journal of Radiation Research.2015; 56(2): 397. CrossRef
Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma
Z. Chu, H. Lin, X. Liang, R. Huang, J. Tang, Y. Bao, J. Jiang, Q. Zhan, X. Zhou
Japanese Journal of Clinical Oncology.2015; 45(7): 637. CrossRef
Correlation of Various Biomarkers with Axillary Nodal Metastases: Can a Panel of Such Biomarkers Guide Selective Use of Axillary Surgery in T1 Breast Cancer?
Tufale A. Dass, Sharma Rakesh, K. Patil Prakash, Chandraveer Singh
Indian Journal of Surgical Oncology.2015; 6(4): 346. CrossRef
Setup Error and Effectiveness of Weekly Image-Guided Radiation Therapy of TomoDirect for Early Breast Cancer
Mi Joo Chung, Guk Jin Lee, Young Jin Suh, Hyo Chun Lee, Sea-Won Lee, Songmi Jeong, Jeong Won Lee, Sung Hwan Kim, Dae Gyu Kang, Jong Hoon Lee
Cancer Research and Treatment.2015; 47(4): 774. CrossRef
Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis
Zhen-Yu He, San-Gang Wu, Qi Yang, Jia-Yuan Sun, Feng-Yan Li, Qin Lin, Huan-Xin Lin
Medicine.2015; 94(48): e2213. CrossRef
Irinotecan and Capecitabine Combination Chemotherapy in a Patient with Triple-negative Breast Cancer Relapsed after Adjuvant Chemotherapy with Anthracycline and Taxane
Anna Lee, Se-Il Go, Won Sup Lee, Un Seok Lee, Moon Jin Kim, Myoung Hee Kang, Gyeong-Won Lee, Hoon-Gu Kim, Jung Hun Kang, Kyung-Nyeo Jeon, Jae Min Cho, Jeong-Hee Lee
Tumori Journal.2015; 101(1): e9. CrossRef
A Prediction Model for the Presence of Axillary Lymph Node Involvement in Women with Invasive Breast Cancer: A Focus on Older Women
Lauren T. Greer, Martin Rosman, W. Charles Mylander, Wen Liang, Robert R. Buras, Anees B. Chagpar, Michael J. Edwards, Lorraine Tafra
The Breast Journal.2014; 20(2): 147. CrossRef
Predictive Role of Tumor Size in Breast Cancer with Axillary Lymph Node Involvement - Can Size of Primary Tumor be used to Omit an Unnecessary Axillary Lymph Node Dissection?
Elahe Orang, Eisa Tahmasbpour Marzony, Aboulfazl Afsharfard
Asian Pacific Journal of Cancer Prevention.2013; 14(2): 717. CrossRef
Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy
Jong Hoon Lee, Jin Ho Song, Sang Nam Lee, Jin Hyoung Kang, Min Sik Kim, Dong Il Sun, Yeon-Sil Kim
Cancer Research and Treatment.2013; 45(1): 31. CrossRef
The Association between Sentinel Lymph Node Metastasis and Ki-67 Labeling Index
Yu Koyama, Hiroshi Ichikawa, Jun Sakata, Eiko Sakata, Kumiko Tatsuda, Miki Hasegawa, Chie Toshikawa, Naoko Manba, Mayuko Ikarashi, Toshifumi Wakai
Advances in Breast Cancer Research.2013; 02(03): 60. CrossRef
Evaluation of ER-α, ER-β1 and ER-β2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers
Huiming Zhang, Zhongtao Zhang, Lixue Xuan, Shan Zheng, Lei Guo, Qimin Zhan, Xiang Qu, Baoning Zhang, Yu Wang, Xiang Wang, Yongmei Song
Clinical and Translational Oncology.2012; 14(3): 225. CrossRef
Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma
C. Ngô, D. Mouttet, Y. De Rycke, F. Reyal, V. Fourchotte, F. Hugonnet, M.C. Falcou, F.C. Bidard, A. Vincent-Salomon, A. Fourquet, S. Alran
European Journal of Surgical Oncology (EJSO).2012; 38(12): 1211. CrossRef
The Incidence and Predictor of Lymph Node Metastasis for Patients with T1mi Breast Cancer Who Underwent Axillary Dissection and Breast Irradiation: An Institutional Analysis
J. H. Lee, Y. J. Suh, B. Y. Shim, S. H. Kim
Japanese Journal of Clinical Oncology.2011; 41(10): 1162. CrossRef
Predictive Factors Affecting Axillary Lymph Node Metastasis in Patients with Invasive Breast Carcinoma of 1 cm or Less
Sun Hee Kang, Jihyung Cho
Journal of the Korean Surgical Society.2011; 80(1): 10. CrossRef
Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma
Sibel Yenidunya, Reyhan Bayrak, Hacer Haltas
Diagnostic Pathology.2011;[Epub] CrossRef
Distance of Breast Cancer From the Skin and Nipple Impacts Axillary Nodal Metastases
Bijan Ansari, Marilyn J. Morton, Darcy L. Adamczyk, Katie N. Jones, Julie K. Brodt, Amy C. Degnim, James W. Jakub, Christine M. Lohse, Judy C. Boughey
Annals of Surgical Oncology.2011; 18(11): 3174. CrossRef
The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma
Fabien Reyal, Roman Rouzier, Berenice Depont-Hazelzet, Marc A. Bollet, Jean-Yves Pierga, Severine Alran, Remy J. Salmon, Virginie Fourchotte, Anne Vincent-Salomon, Xavier Sastre-Garau, Martine Antoine, Serge Uzan, Brigitte Sigal-Zafrani, Yann De Rycke, Xi
PLoS ONE.2011; 6(5): e20297. CrossRef
A Straightforward but Not Piecewise Relationship between Age and Lymph Node Status in Chinese Breast Cancer Patients
Ke-Da Yu, Jun-Jie Li, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Zhi-Ming Shao, Joseph Najbauer
PLoS ONE.2010; 5(6): e11035. CrossRef

11,609 View
117 Download
43 Crossref

Clinical Characteristics of Primary Peritoneal Carcinoma: Sang Young Roh, Sook Hee Hong, Yoon Ho Ko, Tae Hee Kim, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, In Sook Woo, Jin Hyoung Kang, Young Seon Hong, Kyung Shik Lee; Cancer Res Treat. 2007;39(2):65-68. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.65

Abstract PDF PubReader ePub

Purpose

The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC).

Materials and Methods

A retrospective clinical study was conducted to evaluate 22 women diagnosed with a PPC from 1993 to 2007 at the Hospitals of The Catholic University of Korea. Diagnoses were based on the Gynecologic Oncology Group criteria and clinical data. We collected patient clinicopathological data including age, presenting symptoms, pretreatment CA-125 values (U/ml), clinical stage (based on the FIGO stage), performance status (using the Eastern Cooperative Oncology Group scale), whether cytoreductive surgery was optimal or not, types of chemotherapy and response to treatment. We evaluated the clinical characteristics and response to treatment, time to treatment failure and overall survival.

Results

The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13%). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38~18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p<0.05).

Conclusion

We evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.

Citations

Citations to this article as recorded by

Incidentally Diagnosed Low-Grade Primary Peritoneal Serous Carcinoma Within the Umbilical Hernia Sac in a Male: A Report of an Extremely Rare Case and Review of the Literature
Samer Ganam, Ayesha Khan, Nicole Riddle, Joseph A Sujka, Christopher G DuCoin
Cureus.2024;[Epub] CrossRef
Primary peritoneal serous carcinoma – A rare case report
Pradnya Neelakanta Reddy, Eugene J S D'Souza, Avinash Anand
IP Journal of Diagnostic Pathology and Oncology.2024; 9(4): 244. CrossRef
Primary peritoneal high-grade serous carcinoma in a man: A case report
Abdelali Guellil, Rachid Jabi, Mohamed Yassine Mabrouk, Laila Bouzayan, Abdelali Merhoum, Gérald Del Gallo, Claire Godart, Mohammed Bouziane
Annals of Medicine and Surgery.2022; 77: 103605. CrossRef
Primary Peritoneal Carcinoma: A Rare Malignancy Presenting a Diagnostic Challenge
Mariam Shabbir, Sonu Sahni, Meena Ahluwalia, Raji Ayinla
Cureus.2022;[Epub] CrossRef
A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide
Shunichi Kawamura, Toshio Kubo, Kenji Takada, Ryota Sunami, Sachi Okawa, Yoshitaka Iwamoto, Atsuko Hirabae, Akihiko Taniguchi, Yoshinobu Maeda, Katsuyuki Kiura, Masahiro Tabata
International Cancer Conference Journal.2021; 10(3): 197. CrossRef
Primary peritoneal mucinous cystadenocarcinoma mimicking possible recurrent ovarian mucinous cystadenoma: coincidental pathology or a spectrum of disease?
Claire Filippini, Sarah Smyth, Hooman Soleymani Majd, Catherine Johnson
BMJ Case Reports.2021; 14(7): e242478. CrossRef
Imaging features of primary peritoneal serous carcinoma: A case report
Ji Soo Oh, Beum Jin Kim, Myoung Jin Ju, Eun Ae Yoo
Radiology Case Reports.2020; 15(7): 978. CrossRef
Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases
Mingming Sun, Lingjie Bao, Haoran Shen, Min Ji, Liangqing Yao, Xiaofang Yi, Wei Jiang
Taiwanese Journal of Obstetrics and Gynecology.2019; 58(5): 626. CrossRef
Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma
Jin Wook Lee, Eun Taek Park
The Korean Journal of Pancreas and Biliary Tract.2018; 23(2): 54. CrossRef
Inguinal Lymph Node Metastasis of a Primary Serous Papillary Carcinoma of the Peritoneum One Year after CRS and HIPEC
Shadi Katou, Mathilde Feist, Wieland Raue, Johann Pratschke, Beate Rau, Andreas Brandl
Visceral Medicine.2018; 34(4): 307. CrossRef
Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma
Dong Mi, Yuexiang Zhang
The International Journal of Biological Markers.2018; 33(4): 395. CrossRef
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review
Jingping Yuan, Liang He, Bing Han, Yan Li
World Journal of Surgical Oncology.2017;[Epub] CrossRef
An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma
Jinnie S. Y. Pang, Liying Yang, Ghee Kheng Chew, Min Hoe Chew
International Journal of Colorectal Disease.2016; 31(3): 717. CrossRef
Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature
WOO-SUNG YUN, JUNG-MIN BAE
Oncology Letters.2016; 11(6): 4063. CrossRef
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih, Angeles Alvarez Secord
Gynecologic Oncology Research and Practice.2015;[Epub] CrossRef
Amylase-Producing Primary Peritoneal Carcinoma
Ji-Woon Lee, Sang-Gon Park
The Korean Journal of Medicine.2015; 89(3): 358. CrossRef
Solitary primary peritoneal carcinoma arising from the omentum
Yi-Jou Tai, Ming-Chieh Lin, Chin-Jui Wu, Chi-An Chen, Wen-Fang Cheng
Taiwanese Journal of Obstetrics and Gynecology.2014; 53(2): 256. CrossRef
Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
Skyler B. Johnson, Joann I. Prisciandaro, Jessica Zhou, Scott W. Hadley, R. Kevin Reynolds, Shruti Jolly
Journal of Applied Clinical Medical Physics.2014; 15(1): 202. CrossRef
Embryonic natural orifice transumbilical endoscopic surgery (E-NOTES) for adnexal tumors
Myong Cheol Lim, Tae-Joong Kim, Sokbom Kang, Duk-Soo Bae, Sang-Yoon Park, Sang-Soo Seo
Surgical Endoscopy.2009; 23(11): 2445. CrossRef

10,495 View
92 Download
19 Crossref

Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma: Sook Hee Hong, Young Seon Hong, In Sook Woo, Yoon Ho Koh, Sang Young Rho, Ji Yean Peak, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, Ji Chan Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim; Cancer Res Treat. 2007;39(2):54-60. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.54

Abstract PDF PubReader ePub

Purpose

High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL.

Materials and Methods

Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m² Ara-C and 100 mg/m² melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease.

Results

Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1~62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3.

Conclusion

The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.

Citations

Citations to this article as recorded by

Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis
Chengqing Li, Wenyi Guo, Shihong Chen, Jianwei Xu, Feng Li, Lei Wang
Journal of Pancreatology.2022; 5(2): 49. CrossRef

9,784 View
55 Download
1 Crossref

Case Reports

Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman: Hoon-Kyo Kim, Myeong Im Ahn, Jinyoung Yoo, Chi Hong Kim, Hong-Jun Yang, Byoung Yong Shim; Cancer Res Treat. 2007;39(1):37-39. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.37

Abstract PDF PubReader ePub

A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib as a second line treatment, which resulted in a partial response with response duration of 6 months. After progression of the disease, the patient received erlotinib, which resulted in partial response again with response duration of 11.5 months. This observation suggests that treatment with erlotinib may be effective in patients who develop progressive disease after a primary treatment with gefitinib following an initial response.

Citations

Citations to this article as recorded by

Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Navneet Singh
World Journal of Clinical Oncology.2014; 5(5): 858. CrossRef
Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
Sung Chul Hong, Yun Su Sim, Jin Hwa Lee, Yon Ju Ryu, Jung Hyun Chang
Tuberculosis and Respiratory Diseases.2011; 71(4): 286. CrossRef

10,029 View
61 Download
2 Crossref

Hypersensitivity Reactions to Oxaliplatin: Kyoung-Hwan Lee, Yong Jai Park, Eun Sun Kim, Hui Jeong Hwang, Byoung Yong Shim, Hoon-Kyo Kim; Cancer Res Treat. 2006;38(4):240-241. Published online December 31, 2006; DOI: https://doi.org/10.4143/crt.2006.38.4.240

Abstract PDF PubReader ePub

Oxaliplatin is a third-generation platinum compound that is used as a single agent and in combination with fluorouracil (5-FU) to treat colorectal and gastric carcinoma. The patients treated with oxaliplatin may develop hypersensitivity and idiosyncratic reactions, although these complications are known to be rare. We report here on two patients who suffered with metastatic colorectal cancer and who underwent palliative combination chemotherapy with oxaliplatin; they then developed hypersensitivity reactions to oxaliplatin. The first case had an anaphylatic reaction immediately after the beginning of the 7^th to 8^th cycle infusion of oxaliplatin. The second case developed repeated febrile episodes from the 4^th to 8^th cycles of oxaliplatin infusion. With the increasing use of oxaliplatin in clinical practice, we are now encountering an increasing incidence of suspected hypersensitivity reactions. Physicians should keep their eyes wide open and carefully observe for the clinical manifestations of these hypersensitivity reactions.

Citations

Citations to this article as recorded by

A case report of an adverse drug reaction with a combination of oxaliplatin and perindopril
Christina Okello
Journal of Case Reports and Images in Oncology.2022; 7(1): 1. CrossRef
Delayed hypersensitivity to oxaliplatin in a nigerian patient with colorectal cancer—A case report
Usman M Aliyu, Charles O Okwonna
Journal of Oncology Pharmacy Practice.2021; 27(5): 1258. CrossRef
Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer
Siva Naga S Yarrarapu, Austin B Govero, Faeq R Kukhon, Devang K Sanghavi
BMJ Case Reports.2021; 14(4): e240938. CrossRef
Atypical presentation of fever as hypersensitivity reaction to oxaliplatin
Arushi Khurana, Demytra Mitsis, Gurukripa N Kowlgi, Lisa M Holle, Jessica M Clement
Journal of Oncology Pharmacy Practice.2016; 22(2): 319. CrossRef
Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans
Mi-Yeong Kim, Sung-Yoon Kang, Suh-Young Lee, Min-Suk Yang, Min-Hye Kim, Woo-Jung Song, Sae-Hoon Kim, Yo-Jung Kim, Keun-Wook Lee, Sang-Heon Cho, Kyung-Up Min, Jong-Seok Lee, Jee-Hyun Kim, Yoon-Seok Chang
Asian Pacific Journal of Cancer Prevention.2012; 13(4): 1209. CrossRef
Revisión de las reacciones de hipersensibilidad a antineoplásicos
S. Cortijo-Cascajares, M.J. Jiménez-Cerezo, A. Herreros de Tejada
Farmacia Hospitalaria.2012; 36(3): 148. CrossRef

7,794 View
98 Download
6 Crossref

Original Articles

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m²) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy: Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim; Cancer Res Treat. 2005;37(6):339-343. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.339

Abstract PDF PubReader ePub

Purpose

When used in the second-line setting, single-agent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. We studied the safety and efficacy of using second-line single docetaxel (75 mg/m²) for advanced NSCLC patients who were previously treated with platinum-based chemotherapy in Korea.

Materials and Methods

Thirty-three patients with advanced NSCLC received chemotherapy from May 2002 to January 2005. We retrospectively reviewed the charts of these patients. The patients received 75 mg/m² of doxetaxel on day 1 and this was repeated at 3-week intervals.

Results

The median age was 63 years (range: 42~77 years); 16 patients had adenocarcinoma and 8 patients had squamous cell carcinoma. The median number of cycles was 4 (range: 1~7 cycles). Of the 33 patients, 6 patients had partial responses, 13 patients had stable disease and 14 patients had progressive disease. The response rate was 18.2%. The median overall survival was 11 months (range: 7~15 months), and the median progression free survival was 5 months (range: 3~7 months). The median response duration was 5 months (range: 4~9 months). A total of 137 cycles were evaluated for toxicity. We observed grade 3 or 4 neutropenia in 79 cycles (57.6%), grade 3 or 4 leukopenia in 46 cycles (33.6%), and grade 3 febrile neutropenia in 2 cycles (1.5%). The median nadir day was day 9 (range: day 5~19), and the median number of G-CSF injections was 2 (range: 0~6). The most common non-hematologic toxicities were myalgia/arthralgia and neurotoxicity, but any grade 3 or 4 non-hematologic toxicity was not observed. The major toxicity of this therapy was neutropenia. The absolute neutrophil count decreased relatively rapidly, but neutropenic fever or related infection was rare. There were no treatment-related deaths.

Conclusion

These results revealed a satisfactory response rate (18.2%) with using docetaxel as the second-line chemotherapy for NSCLC. The second-line docetaxel was an active and well-tolerated regimen in patients with advanced NSCLC pretreated with platinum-based chemotherapy.

Citations

Citations to this article as recorded by

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Yongchang Zhang, Lianxi Song, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Zhan Wang, Qing Xia, Wenjuan Jiang, Qinqin Xu, Nong Yang
BMC Cancer.2022;[Epub] CrossRef
Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
JoungSoon Jang, Hoon-Kyo Kim, Byoung Chul Cho, Kyung Hee Lee, Hwan-Jung Yun, In Sook Woo, Hong Suk Song, Hun-Mo Ryoo, Chi-Hong Kim, Der-Sheng Sun, Jong Wook Shin
Cancer Chemotherapy and Pharmacology.2017; 79(5): 873. CrossRef
Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review
Ricardo Fernandes, Sasha Mazzarello, Habeeb Majeed, Stephanie Smith, Risa Shorr, Brian Hutton, Mohammed FK Ibrahim, Carmel Jacobs, Michael Ong, Mark Clemons
Supportive Care in Cancer.2016; 24(4): 1583. CrossRef
Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
Keun-Wook Lee, Joo Han Lim, Jee Hyun Kim, Choon-Taek Lee, Jong Seok Lee
Journal of Korean Medical Science.2008; 23(6): 992. CrossRef
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
The Korean Journal of Internal Medicine.2007; 22(3): 178. CrossRef

10,516 View
68 Download
5 Crossref

Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer: Byoung Yong Shim, Kang Moon Lee, Hyeon-Min Cho, Hyun Jin Kim, Hong Joo Cho, Jinmo Yang, Jun-Gi Kim, Hoon-Kyo Kim; Cancer Res Treat. 2005;37(4):212-215. Published online August 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.4.212

Abstract PDF PubReader ePub

Purpose

Fluorouracil (5-FU) and leucovorin combination therapy have shown synergistic or additive effect against advanced colorectal cancer, but the frequency of mucositis and diarrhea is increased. Most previous studies have used high dose leucovorin (300~500 mg/m²). However, some studies of oxaliplatin and 5-FU with low-dose or high-dose leucovorin in Korea have shown similar response rates. Therefore, we studied the necessity of leucovorin and evaluated the objective tumor response rates and toxicities of a regimen of oxaliplatin and 5-FU without leucovorin every 2 weeks in metastatic colorectal cancer patients.

Materials and Methods

Twenty-four patients with metastatic colorectal cancer were enrolled between January 2002 and March 2003. Patients received 85 mg/m² of oxaliplatin on day 1, a bolus 5-FU 400 mg/m² on day 1 and a continuous 5-FU infusion at 600 mg/m²/ 22 hours days 1 and 2, every 2 weeks.

Results

Of the 24 patients treated, 17 patients received previous 5FU with leucovorin and/or other chemotherapy. Three patients could not be evaluated. Five partial responses were observed with overall response rate of 21% (n=24). Of the previous chemotherapy group (n=17), 4 partial responses were observed with response rate of 24%. Median overall survival was 18 months (range 4~32 months) and median progression free survival was 4 months (range 2~6 months). This regimen was well tolerated and only 1 grade 3 anemia was observed.

Conclusion

Oxaliplatin/5-FU combination therapy without leucovorin achieved a relatively high response rate even in patients resistant to the previous 5-FU chemotherapy, and toxicity was minimal.

Citations

Citations to this article as recorded by

Clinicopathological Features and Oncological Outcomes of Early and Late Recurrence in Stage III Colorectal Cancer Patients after Adjuvant Oxaliplatin-Based Therapy
Yu-Tang Chang, Hsiang-Lin Tsai, Yen-Cheng Chen, Ching-Chun Li, Ching-Wen Huang, Po-Jung Chen, Wei-Chih Su, Tsung-Kun Chang, Yung-Sung Yeh, Tzu-Chieh Yin, Jaw-Yuan Wang, Weiren Luo
Journal of Oncology.2023; 2023: 1. CrossRef
Targeting the SPHK1/HIF1 Pathway to Inhibit Colorectal Cancer Stem Cells Niche
Saeideh Gholamzadeh Khoei, Hamid Sadeghi, Fateme Karimi Dermani
Journal of Gastrointestinal Cancer.2020; 51(2): 716. CrossRef
Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer
Maria Toloudi, Panagiotis Apostolou, Ioannis Papasotiriou
Journal of Cancer Therapy.2015; 06(04): 345. CrossRef
Gene Expression Changes in Colorectal Cancer during Metronomic Chemotherapy and High-Concentration Drug Administration
Panagiotis Apostolou, Maria Toloudi, Irene Kalliara, Vasiliki Kipourou, Ioanna Tourna, Ioannis Papasotiriou
Journal of Cancer Therapy.2015; 06(08): 679. CrossRef

10,154 View
45 Download
4 Crossref

Expression of Caspase-3 and c-myc in Non-Small Cell Lung Cancer: Jin young Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Suji Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Seok Jin Kang, Hoon Kyo Kim; Cancer Res Treat. 2004;36(5):303-307. Published online October 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.303

Abstract PDF PubReader ePub

Purpose

Caspase-3 is a cysteine protease that plays an important role in the process of apoptotic cell death, but little has been studied clinically on caspase-3 in lung cancer. Increased c-myc expression can result in mitosis or apoptosis, and its contribution to the pathogenesis and prognosis of lung cancer has gained interest. In the present study, the expressions of caspase-3 and c-myc, along with their possible correlations with prognostic variables, were analyzed in resected non-small cell lung carcinomas (NSCLC).

Materials and Methods

Archival tumor tissues from 147 previously untreated NSCLC patients were examined by immunohistochemistry for the expressions of caspase-3 and c-myc proteins. Clinical information was obtained through the computerized retrospective database from the tumor registry.

Results

The expressions of caspase-3 and c-myc were detected in 60 (88/147) and 16% (24/147) of tumors, respectively. No association was found between caspase-3 and c-myc expressions. A multivariate analysis demonstrated the N status and pathologic stage to be significantly correlated with poor survival (p-value=.018 and .002, respectively), but positive expression of caspase-3 was associated with a good prognosis (p=.03).

Conclusion

Our data suggest the involvement of caspase-3 in the tumorigenesis of NSCLC. It is also noteworthy that caspase-3 expression might be a favorable prognostic indicator in these tumors.

Citations

Citations to this article as recorded by

DNA Damage-Induced Ferroptosis: A Boolean Model Regulating p53 and Non-Coding RNAs in Drug Resistance
Shantanu Gupta, Daner A. Silveira, José Carlos M. Mombach, Ronaldo F. Hashimoto
Proteomes.2025; 13(1): 6. CrossRef
Highly in vitro anti-cancer activity of melittin-loaded niosomes on non-small cell lung cancer cells
Pooyan Honari, Delavar Shahbazzadeh, Mahdi Behdani, Kamran Pooshang Bagheri
Toxicon.2024; 241: 107673. CrossRef
Neuropilin-1 Binding Peptide as Fusion to Diphtheria Toxin Induces Apoptosis in Non-small Cell Lung Cancer Cell Line
Sara Eghtedari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht
Current Pharmaceutical Design.2024; 30(17): 1317. CrossRef
Antiproliferative effect of indeno[1,2-d]thiazolo[3,2-a]pyrimidine analogues on IL-6 mediated STAT3 and role of the apoptotic pathway in albino Wistar rats of ethyl carbamate-induced lung carcinoma: In-silico, In-vitro, and In-vivo study
Archana Bharti Sonkar, Abhishek Verma, Sneha Yadav, Rohit Kumar, Jyoti Singh, Amit K. Keshari, Soniya Rani, Anurag Kumar, Dharmendra Kumar, Neeraj Kumar Shrivastava, Shubham Rastogi, Mariam K. Alamoudi, Mohd Nazam Ansari, Abdulaziz S. Saeedan, Gaurav Kait
Cancer Cell International.2024;[Epub] CrossRef
The Effect of Continuous Positive Airway Pressure (CPAP) Therapy on Serum Caspase-3 Level in Patients with Obstructive Sleep Apnea (OSA)
Mustafa Kemal Kaypak, Ali Nihat Annakkaya, Fatih Davran, Pınar Yıldız Gülhan, Uğur Yüregir
Sleep and Breathing.2024; 28(4): 1597. CrossRef
The concealed side of caspases: beyond a killer of cells
Lina Abdelghany, Chanin Sillapachaiyaporn, Boris Zhivotovsky
Cellular and Molecular Life Sciences.2024;[Epub] CrossRef
The Expression of Caspase-3 and GRIM-19 in Non-mucinous Lung Adenocarcinoma and Their Clinicopathologic Significance
Alev OK ATILGAN, Merih TEPEOĞLU, Eda YILMAZ AKÇAY, Leyla HASANALİYEVA, Dalokay KILIÇ, Handan ÖZDEMİR
Düzce Tıp Fakültesi Dergisi.2023; 25(2): 158. CrossRef
Increasing Apoptotic Effect of Cord Blood and Wharton's Jelly-derived Mesenchymal Stem Cells on HT-29
Figen Abatay-Sel, Ayse Erol, Mediha Suleymanoglu, Gokhan Demirayak, Cigdem Kekik-Cinar, Durdane Serap Kuruca, Fatma Savran-Oguz
Current Stem Cell Research & Therapy.2023; 18(8): 1133. CrossRef
Multimolecular characteristics of cell-death related hub genes in human cancers: a comprehensive pan-cancer analysis
Dingtao Hu, Tingyu Zhang, Ziye Yan, Linlin Wang, Yuhua Wang, Nana Meng, Bizhi Tu, Ying Teng, Zhen Li, Xiaoqi Lou, Yu Lei, Xiaoshuang Ren, Yanfeng Zou, Fang Wang
Cell Cycle.2022; 21(22): 2444. CrossRef
Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study
Jin Cao, Juan J Gu, Yichen Liang, Buhai Wang
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Global profiling of lncRNAs-miRNAs-mRNAs reveals differential expression of coding genes and non-coding RNAs in the lung of beagle dogs at different stages of Toxocara canis infection
Wen-Bin Zheng, Yang Zou, Jun-Jun He, Hany M. Elsheikha, Guo-Hua Liu, Min-Hua Hu, Shui-Lian Wang, Xing-Quan Zhu
International Journal for Parasitology.2021; 51(1): 49. CrossRef
Prognostic Significance of Eight Immune-Related Genes on Survival in Patients with Lung Squamous Cell Carcinoma
Hansheng Wu, Shujie Huang, Weitao Zhuang, Guibin Qiao
Biomarkers in Medicine.2021; 15(4): 295. CrossRef
Antitumor Effects of Carvacrol and Thymol: A Systematic Review
Laeza Alves Sampaio, Lícia Tairiny Santos Pina, Mairim Russo Serafini, Débora dos Santos Tavares, Adriana Gibara Guimarães
Frontiers in Pharmacology.2021;[Epub] CrossRef
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Daniel Massó-Vallés, Marie-Eve Beaulieu, Laura Soucek
Expert Opinion on Therapeutic Targets.2020; 24(2): 101. CrossRef
RETRACTED ARTICLE: A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers
Poonam Parashar, Chandra Bhushan Tripathi, Malti Arya, Jovita Kanoujia, Mahendra Singh, Abhishek Yadav, Shubhini A. Saraf
Drug Delivery and Translational Research.2019; 9(1): 37. CrossRef
miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9
Haitao Huang, Yuxuan Wang, Qin Li, Xiaoyan Fei, Haitao Ma, Rongkuan Hu
Cancer Letters.2019; 446: 81. CrossRef
Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival
Xuan Pu, Sarah J. Storr, Yimin Zhang, Emad A. Rakha, Andrew R. Green, Ian O. Ellis, Stewart G. Martin
Apoptosis.2017; 22(3): 357. CrossRef
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Eun Young Kim, Arum Kim, Se Kyu Kim, Yoon Soo Chang
Lung Cancer.2017; 110: 63. CrossRef
Caspase-3 expression in tumorigenesis and prognosis of buccal mucosa squamous cell carcinoma
Jer-Shyung Huang, Cheng-Mei Yang, Jyh-Seng Wang, Huei-Han Liou, I-Chien Hsieh, Guan-Cheng Li, Sin-Jhih Huang, Chih-Wen Shu, Ting-Ying Fu, Yun-Chung Lin, Luo-Ping Ger, Pei-Feng Liu
Oncotarget.2017; 8(48): 84237. CrossRef
An epigenetic auto-feedback loop regulates TGF-β type II receptor expression and function in NSCLC
Shanzhong Yang, Yong-Jig Cho, Lin Jin, Guandou Yuan, Arunima Datta, Phillip Buckhaults, Pran K. Datta
Oncotarget.2015; 6(32): 33237. CrossRef
Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas
Yari Ciribilli, Prashant Singh, Reinhard Spanel, Alberto Inga, Jürgen Borlak
Oncotarget.2015; 6(31): 31569. CrossRef
Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells
Jui-Chieh Chen, Yen-Hao Su, Ching-Feng Chiu, Yi-Wen Chang, Yang-Hao Yu, Chi-Feng Tseng, Hsin-An Chen, Jen-Liang Su
Annals of Surgical Oncology.2014; 21(S4): 555. CrossRef
Retracted: MiR‐449c targets c‐Myc and inhibits NSCLC cell progression
Li-Jun Miao, Shi-Fu Huang, Zhen-Tao Sun, Zeng-Yan Gao, Rui-xia Zhang, Ying Liu, Jing Wang
FEBS Letters.2013; 587(9): 1359. CrossRef
The Evaluation of Immunohistochemical Markers and Thymic Cortical Microenvironmental Cells in Distinguishing Thymic Carcinoma from Type B3 Thymoma or Lung Squamous Cell Carcinoma
Atsushi Hayashi, Takumi Fumon, Yukari Miki, Hiaki Sato, Tadashi Yoshino, Kiyoshi Takahashi
Journal of Clinical and Experimental Hematopathology.2013; 53(1): 9. CrossRef
Protein Signature of Lung Cancer Tissues
Michael R. Mehan, Deborah Ayers, Derek Thirstrup, Wei Xiong, Rachel M. Ostroff, Edward N. Brody, Jeffrey J. Walker, Larry Gold, Thale C. Jarvis, Nebojsa Janjic, Geoffrey S. Baird, Sheri K. Wilcox, Rossella Rota
PLoS ONE.2012; 7(4): e35157. CrossRef

11,024 View
70 Download
25 Crossref

Expression of c-kit and p53 in Non-small Cell Lung Cancers: Jinyoung Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Sung Whan Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Hoon-Kyo Kim; Cancer Res Treat. 2004;36(3):167-172. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.167

Abstract PDF PubReader ePub

Purpose

Increasing experimental evidence indicates that abnormal expression of c-kit may be implicated in the pathogenesis of a variety of solid tumors. It has been reported that over 70% of small cell lung cancer (SCLC) contain the c-kit receptor. In the present study, a c-kit analysis has been extended to non-small cell lung cancer (NSCLC). The expressions of p53, vascular endothelial growth factor (VEGF) and cd34, in addition to c-kit, were evaluated to investigate the correlations between these proteins and to determine their potential relationships with the clinicopathological data.

Materials and Methods

Paraffin-embedded tumor sections, obtained from 147 patients with NSCLC, were immunohistochemically investigated using anti-c-kit, anti-p53, anti-VEGF and anti-cd34 antibodies.

Results

c-kit was expressed in 40 (27%) of the tumors examined: 27% of the adenocarcinomas, 27% of the squamous cell carcinomas and 29% of the undifferentiated carcinomas. p53 and VEG F immunoreactivities were present in 107 (73%) and 110 (75%) carcinomas, respectively. Anti-cd34 was negative in all samples. No associations were established among these proteins. The c-kit, however, showed a strong correlation with the T factor: T1 (n=11), 0%; T2 (n=49), 16% and T3 (n=87), 37% (p=.006).

Conclusion

It is suggested that in NSCLC c-kit is expressed relatively frequently and may become a therapeutic target for the patients with inoperable or recurrent c-kit positive tumors. The alterations in p53 probably constitute an early event, whereas the activated c-kit may contribute to tumor progression.

Citations

Citations to this article as recorded by

Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis
Ying Su, Ru Chen, Zhongcheng Han, Rong Xu, Lili Ma, Reyina Wufuli, Hongbo Liu, Fang Wang, Lei Ma, Rui Chen, Jiang Liu
Pathobiology.2021; 88(4): 267. CrossRef
A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
Ernest Osei, Julia Lumini, Dinindu Gunasekara, Beverley Osei, Akua Asare, Raymond Laflamme
Journal of Radiotherapy in Practice.2020; 19(4): 370. CrossRef
Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression
Mi Zhang, Jing Liang, Shi-Kun Jiang, Ling Xu, Yan-Ling Wu, Annoor Awadasseid, Xiao-Yin Zhao, Xu-Qiong Xiong, Hiroshi Sugiyama, Wen Zhang
European Journal of Medicinal Chemistry.2020; 207: 112704. CrossRef
Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer
HUI XIAO, JUAN WANG, YANAN LIU, LI LI
Oncology Letters.2014; 8(2): 582. CrossRef
Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer
Misun Park, Won Kyu Kim, Meiying Song, Minhee Park, Hyunki Kim, Hye Jin Nam, Sung Hee Baek, Hoguen Kim
Clinical Cancer Research.2013; 19(18): 4961. CrossRef

9,094 View
62 Download
5 Crossref

First
Prev
Page of 1
Next
Last

Search